Targeting the RAS oncogene

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert opinion on therapeutic targets

• Publication date

  2013-04-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/14728222.2013.764990PMID 23360111PMCID PMC3804031
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract 2342: Inhibition of protein kinase C delta induces apoptosis through JNK-H2AX pathway in melanoma.

  2013cited by this paper
• RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

  2013cited by this paper
• Abstract 3737: The PI3K/mTOR inhibitor PWT33597 regresses 786-0 renal xenografts

  2012cited by this paper
• Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.

  2012cited by this paper
• RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

  2012cited by this paper
• A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.

  2012cited by this paper
• Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors.

  2012cited by this paper
• A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).

  2012cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

  2012cited by this paper
• The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion.

  2012cited by this paper
• First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.

  2012cited by this paper
• Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models

  2012cited by this paper
• A comprehensive survey of Ras mutations in cancer.

  2012influential reference
• Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.

  2012cited by this paper
• Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.

  2012cited by this paper
• Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

  2012influential reference
• Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus

  2012influential reference
• RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

  2012cited by this paper
• PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

  2012cited by this paper
• PX-866 and docetaxel in patients with advanced solid tumors.

  2012cited by this paper
• Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

  2012cited by this paper
• Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

  2012influential reference
• Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

  2012cited by this paper
• Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

  2012cited by this paper
• Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

  2012cited by this paper
• Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

  2012cited by this paper
• The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors.

  2012cited by this paper
• Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor

  2012cited by this paper
• A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.

  2012cited by this paper
• A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.

  2012cited by this paper
• Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.

  2012cited by this paper
• Ras in cancer and developmental diseases.

  2011influential reference
• First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

  2011influential reference
• Therapeutic strategies for targeting ras proteins.

  2011influential reference
• Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors.

  2011cited by this paper
• A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)

  2011cited by this paper
• A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

  2011cited by this paper
• A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.

  2011cited by this paper
• GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

  2011influential reference
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

  2011influential reference
• PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

  2011cited by this paper
• GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

  2011influential reference
• Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.

  2011cited by this paper
• Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.

  2011cited by this paper
• Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

  2011influential reference
• A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome

  2011cited by this paper
• Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

  2011cited by this paper
• CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

  2011cited by this paper
• Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

  2011cited by this paper
• CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

  2011cited by this paper
• Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

  2011cited by this paper
• BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

  2011cited by this paper
• Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.

  2011cited by this paper
• Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

  2011cited by this paper
• Abstract 3555: Anti-tumor activity of CAL-101, a potent selective inhibitor of the p110Δ isoform of PI3K, in models of human glioblastoma

  2011cited by this paper
• Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

  2011cited by this paper
• Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.

  2011cited by this paper
• Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

  2011cited by this paper
• Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

  2011cited by this paper
• A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

  2011cited by this paper
• Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.

  2011cited by this paper
• Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).

  2011cited by this paper
• A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).

  2011cited by this paper
• Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

  2011cited by this paper
• A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.

  2011cited by this paper
• STK33 kinase activity is nonessential in KRAS-dependent cancer cells.

  2011cited by this paper
• Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

  2011cited by this paper
• A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

  2011cited by this paper
• The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.

  2011cited by this paper
• Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo

  2010cited by this paper
• Ridaforolimus

  2010cited by this paper
• CNS Disease In Younger Patients (

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• Two Faces of Protein Kinase Cδ: The Contrasting Roles of PKCδ in Cell Survival and Cell Death

  2010cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

  2010cited by this paper
• First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

  2010cited by this paper
• Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival

  2010cited by this paper
• Everolimus

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

  2010cited by this paper
• Everolimus: Fig. 1.

  2010cited by this paper
• The PKB/AKT pathway in cancer.

  2010cited by this paper
• Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition

  2010cited by this paper
• A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

  2010cited by this paper
• MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

  2010cited by this paper
• Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

  2010cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma.

  2010cited by this paper
• A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.

  2010cited by this paper
• Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

  2010cited by this paper
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010cited by this paper

• The Role of Gonadotropins and Growth Factor in Regulating Ras During Maturation in Cumulus–Oocyte Complexes of Pigs

  2025cites this paper
• A feed-forward loop between Toll/NF-κB and Rac1 promotes epithelial to mesenchymal transition of Ras-oncogenic hindgut enterocytes in Drosophila

  2025cites this paper
• The Role of RAS in CNS Tumors: A Key Player or an Overlooked Oncogene?

  2025cites this paper
• Advancement in preclinical development of cancer treatment agents through modulation of Rac1: From EHop-016 to natural products.

  2025cites this paper
• First Report of Trametinib‐Nintedanib Combination in KRAS G12D‐Mutated Pancreatic Cancer: Efficacy and Fatal Hemorrhagic Complication: A Case Report

  2025cites this paper
• Ornithine decarboxylase and its role in cancer.

  2025cites this paper
• Targeting KRAS in pancreatic cancer

  2024cites this paper
• Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring

  2024cites this paper
• The Multifaceted Role of miR-21 in Pancreatic Cancers

  2024cites this paper
• Altered hormone expression induced genetic changes leads to breast cancer

  2024cites this paper
• Emerging Targets in Non-Small Cell Lung Cancer

  2024cites this paper
• Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer

  2023cites this paper
• The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy

  2022cites this paper
• Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature

  2022cites this paper
• A critical ETV4/Twist1/Vimentin axis in Ha-RAS-induced aggressive breast cancer

  2022cites this paper
• Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer

  2022cites this paper
• Inhibiting mutant KRAS G12D gene expression using novel peptide nucleic acid-based antisense: A potential new drug candidate for pancreatic cancer

  2022cites this paper
• Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression

  2022cites this paper
• Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

  2021cites this paper
• Targeting KRAS in pancreatic cancer: new drugs on the horizon

  2021cites this paper
• Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence

  2021cites this paper
• KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China

  2021cites this paper
• Prominent roles of ribosomal S6 kinase 4 (RSK4) in cancer.

  2021cites this paper
• Gene expression profiling of giant fibroadenomas of the breast.

  2021cites this paper
• Intense terahertz pulses inhibit Ras signaling and other cancer-associated signaling pathways in human skin tissue models

  2021cites this paper
• Transcriptomics unravels molecular players shaping dorsal lip hypertrophy in the vacuum cleaner cichlid, Gnathochromis permaxillaris

  2021cites this paper
• Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo

  2020cites this paper
• Studying the Effect of Low Doses of Ionization Radiation on Senescence in Human Lung Fibroblasts.

  2020cites this paper
• Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer

  2020cites this paper
• Cholesterol and beyond - The role of the mevalonate pathway in cancer biology.

  2020cites this paper
• miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer

  2020cites this paper
• A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations

  2020cites this paper
• Transcription box-3 protects human umbilical vein endothelial cells in a high-glucose environment through sirtuin 1/AKT signaling

  2020cites this paper
• Targeted Therapy for Non-Small Cell Lung Cancer

  2020cites this paper
• An Inventive Report of Inducing Apoptosis in Non-Small Cell Lung Cancer (NSCLC) Cell Lines by Transfection of MiR-4301.

  2019cites this paper
• The T helper type 17/regulatory T cell imbalance was associated with Ras‐GTPase overexpression in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease

  2019cites this paper
• Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

  2019cites this paper
• Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract

  2019cites this paper
• Targeting Mutant KRAS for Anticancer Therapy.

  2019cites this paper
• The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism

  2019cites this paper
• Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion*

  2019cites this paper
• Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.

  2019cites this paper
• Genomic Mechanisms of THz-Induced Cancer Dysregulation in Human Skin

  2019cites this paper
• Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer

  2019cites this paper
• Serotonin uptake is required for Rac1 activation in Kras‐induced acinar‐to‐ductal metaplasia in the pancreas

  2018cites this paper
• Feedback regulation loop between bonemorphogenetic proteins and theirantagonists in prostate cancer and theimplication in bone metastasis

  2018cites this paper
• Elucidating mechanisms of innate and acquired resistance to PI3Ka inhibition in head and neck squamous cell carcinoma

  2018influential citation
• Topology-Based Prediction of Pathway Dysregulation Induced by Intense Terahertz Pulses in Human Skin Tissue Models

  2018cites this paper
• Topology-Based Prediction of Pathway Dysregulation Induced by Intense Terahertz Pulses in Human Skin Tissue Models

  2018cites this paper
• KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

  2018cites this paper
• Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors

  2018influential citation
• PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.

  2018cites this paper
• Targeted Therapies for Pancreatic Cancer

  2018cites this paper
• PI3K: A Crucial Piece in the RAS Signaling Puzzle.

  2018cites this paper
• Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of β-catenin signaling

  2018cites this paper
• From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions

  2018cites this paper
• ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.

  2018cites this paper
• Rasip1 is a RUNX1 target gene and promotes migration of NSCLC cells

  2018cites this paper
• Silencing IGF‐II impairs C‐myc and N‐ras expressions of SMMC‐7721 cells via suppressing FAK/PI3K/Akt signaling pathway

  2017cites this paper
• Defining the role of the RSK isoforms in cancer.

  2017cites this paper
• Oncogene driver mutations and copy number variation as markers for predicting drug resistance and disease outcome in NSCLC

  2017cites this paper
• Screening of prenyldiphosphate mimetics for their potential to inhibit 4-hydroxybenzoate oligoprenyl transferase

  2017cites this paper
• Functional analysis of long non-coding RNAs in cancer

  2017cites this paper
• Multitarget-Directed Antioxidants as Therapeutic Agents: Putting the Focus on the Oxidative Stress

  2017cites this paper
• Search for Inhibitors of Ras-Driven Cancers

  2017cites this paper
• Role of reactive oxygen species in modulating carbohydrate metabolism in acute myeloid leukaemia

  2017cites this paper
• Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging.

  2017cites this paper
• The RAS-Effector Interaction as a Drug Target.

  2017influential citation
• Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens

  2017cites this paper
• In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor

  2017cites this paper
• Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes

  2016cites this paper
• Pancreatic Cancer from Molecular Pathways to Treatment Opinion

  2016cites this paper
• Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target

  2016cites this paper
• Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras

  2016cites this paper
• CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins

  2016influential citation
• Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells

  2016cites this paper
• Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase).

  2016cites this paper
• 1,25-Dihydroxyvitamin D inhibits glutamine metabolism in Harvey-ras transformed MCF10A human breast epithelial cell.

  2016cites this paper
• Mutation Screening of Her-2, N-ras and Nf1 Genes in Brain Tumor Biopsies.

  2016cites this paper
• Structure, functional regulation and signaling properties of Rap2B.

  2016cites this paper
• Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress.

  2016cites this paper
• Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

  2016cites this paper
• KRAS-related proteins in pancreatic cancer.

  2016cites this paper
• RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma

  2016cites this paper
• Past, Present, and Future of Targeting Ras for Cancer Therapies.

  2016cites this paper
• TW-01, a piperazinedione-derived compound, inhibits Ras-mediated cell proliferation and angioplasty-induced vascular restenosis.

  2016cites this paper
• State of the art biological therapies in pancreatic cancer.

  2016cites this paper
• Glutamate E15 and E171 are Hotspots in p60TRP-Related Cancer

  2016cites this paper
• Quantitative Super-Resolution Microscopy for Cancer Biology and Medicine

  2016cites this paper
• Discovery of Inhibitors of Protein–Protein Interactions Using Fragment‐Based Methods

  2016cites this paper
• The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer

  2015cites this paper
• Aggregation-induced emission (AIE) dye loaded polymer nanoparticles for gene silencing in pancreatic cancer and their in vitro and in vivo biocompatibility evaluation

  2015cites this paper
• The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness.

  2015cites this paper
• 5‐Fluorouracil preferentially sensitizes mutant KRAS non‐small cell lung carcinoma cells to TRAIL‐induced apoptosis

  2015cites this paper
• Molecular biomarkers in colorectal carcinoma.

  2015cites this paper
• Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies

  2015cites this paper
• Cancer - A Story on Fault Propagation in Gene-Cellular Networks

  2015cites this paper
• Hybrid Molecule from Farnesylthiosalicylic Acid‐diamine and Phenylpropenoic Acid as Ras‐related Signaling Inhibitor with Potent Antitumor Activities

  2015cites this paper
• The Ras–Membrane Interface: Isoform-Specific Differences in the Catalytic Domain

  2015cites this paper
• RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

  2015cites this paper